CUPERTINO, Calif., April 1, 2019 /PRNewswire/ -- DURECT Corporation
(Nasdaq: DRRX) announced today that Michael
Arenberg, Chief Financial Officer, will be presenting at the
H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50
a.m. BST / 05.50 a.m.
EDT. The conference is being held at the JW Marriott
Grosvenor House in London. Institutional investors and
analysts that are attending the conference may request a one-on-one
meeting through the conference coordinators.
A live audio webcast of the presentation will be available by
accessing http://wsw.com/webcast/hcw4/drrx.
The live audio webcast of the presentation will also be
available by accessing DURECT's homepage at www.durect.com and
clicking on the "Investors" tab. If you are unable to
participate during the live webcast, the call will be archived on
DURECT's website in the Event Calendar of the "Investors"
section.
Key Opinion Leader (KOL) Call: Updated Logistics
On Wednesday, April 17, 2019 at
11:00am EDT/8:00am PDT, DURECT will be hosting a key opinion
leader (KOL) call providing an overview of nonalcoholic
steatohepatitis (NASH) and its progression, current treatment
options and new treatments in development. The call will feature a
presentation by KOL Brent Tetri, MD, Professor of Internal Medicine
at Saint Louis University. DURECT
will also provide an overview of the Company's development program
for DUR-928 and Dr. Tetri will be available to answer questions
after the presentations.
Updated Dial-In
& Webcast Information
|
Wednesday,
April 17 @ 11:00 am Eastern Time / 8:00 am Pacific
Time
|
Domestic:
|
888-394-8218
|
International:
|
323-794-2588
|
Conference
ID:
|
1264564
|
Webcast
w/Slides:
|
http://public.viavid.com/index.php?id=133834.
|
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury such as Alcoholic Hepatitis (AH) and
acute kidney injury (AKI), hepatic diseases such as nonalcoholic
steatohepatitis (NASH), and inflammatory skin conditions such as
psoriasis and atopic dermatitis. DURECT's advanced oral and
injectable delivery technologies are designed to enable new
indications and enhanced attributes for small-molecule and biologic
drugs. Late stage product candidates in this category include
POSIMIR® (bupivacaine extended-release solution), an
investigational locally-acting, non-opioid analgesic intended to
provide up to 3 days of continuous pain relief after surgery, and
ORADUR®-Methylphenidate ER Capsules, approved in
Taiwan as Methydur Sustained
Release Capsules, where it is indicated for the treatment of
attention deficit hyperactivity disorder (ADHD). In addition,
for the assignment of certain patent rights, DURECT receives single
digit sales-based earn-out payments from U.S. net sales of
Indivior's PERSERIS™ (risperidone) drug for
schizophrenia, which was approved in July
2018 and commercially launched in February 2019. For
more information, please visit www.durect.com.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential use
of DUR-928 to treat chronic hepatic diseases such as NASH, acute
organ injuries such as alcoholic hepatitis (AH) and acute kidney
injury (AKI), and in inflammatory skin disorders such as psoriasis
and atopic dermatitis, the use of POSIMIR to treat post-surgical
pain, the use of Indivior's PERSERIS™ to treat
schizophrenia, as well as the potential commercial sales of
Indivior's PERSERIS are forward-looking statements involving risks
and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential
risks and uncertainties include, but are not limited to, the risk
of delays in the enrollment of the ongoing clinical trials of
DUR-928 in NASH, AH and mild to moderate plaque psoriasis,
potential adverse effects arising from the testing or use of
DUR-928, the risk that the FDA may not approve the POSIMIR NDA, the
risk that PERSERIS will not have a successful launch, our ability
to avoid infringing patents held by other parties and secure and
defend patents of our own patents, and our ability to manage and
obtain capital to fund our operations and expenses. Further
information regarding these and other risks is included in DURECT's
Form 10-K on March 8, 2019 under the
heading "Risk Factors."
NOTE: ORADUR®, POSIMIR® and
SABER® are trademarks of DURECT Corporation.
Other referenced trademarks belong to their respective owners.
DUR-928, ORADUR-Methylphenidate ER Capsules and POSIMIR are drug
candidates under development and have not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities. For PERSERIS full prescribing information visit
www.perseris.com.
View original
content:http://www.prnewswire.com/news-releases/durect-to-present-at-the-hc-wainwright-global-life-sciences-conference-and-host-an-upcoming-kol-call-on-nash-300821468.html
SOURCE DURECT Corporation